We aimed to determine the role of cytomegalovirus (CMV)-infected donor cells in the development of a CMV-specific immune response in kidney transplant recipients.
| INTRODUC TI ON
Human cytomegalovirus (CMV) is a ubiquitous herpes virus that infects 50-90% of people in the United States and Europe, usually during childhood. 1, 2 Following primary infection, a large and powerful anti-CMV immune response, involving both innate and adaptive components, leads to resolution of the acute primary infection and confines it to a restricted number of cells in a latent state. 3 Thus, CMV is not eliminated and persists life-long in its host, with a dynamic subtle equilibrium established between the virus, which needs to multiply to be shed in secretions and to disseminate to a new host, and the anti-CMV immune response.
CMV-specific human leukocyte antigen I (HLA-I)-restricted CD8 + T cells are an important component of the anti-CMV response after organ transplantation. 4 Most blood-borne CMV-specific CD8
+ T cells consist of terminally differentiated effector T cells, also called memory inflation T cells (T EFF , T EMRA ), and a minority of central memory T cells (T CM ) and effector memory T cells (T EM ). T EFF cells are en-
dowed with immediate effector function but have a short life span.
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They are continuously replenished by human CMV-specific T CM or T EM subsets, which divide and differentiate after occasional antigen stimulation by non-haematopoietic cells. 4 These cells, along with resident memory T cells (T RM ), participate in the immune surveillance in latently infected organs. 4, 5 In transplant patients, the use of immunosuppressive drugs and highly frequent events promoting the exit of latency, such as ischemia-reperfusion, sepsis, and alloreactivity, deeply affect the course of CMV infection. In addition, different situations can be encountered depending on the donor and recipient CMV status.
First, latent recipient CMV can be reactivated in the R+ recipient regardless of the donor CMV status. Second, donor CMV reactivation can lead to a reinfection in the D+R+ recipient because CMV is able to establish a secondary persistent infection despite the previous CMV infection and memory CMV-specific immune response, 6, 7 or primary infection in the D+R− recipient. We previously reported donor CMV positivity as a risk factor of graft loss, especially in CMV-infected recipients (D+R+). 8 Also, CMV is commonly detected in transplanted kidneys from CMV-positive donors 9, 10 and replication of CMV within kidney grafts is associated with a poor clinical outcome. 9, 11 In addition, we showed that the deleterious effect of donor CMV positivity on kidney graft outcome was mainly observed in kidney transplant recipients with full HLA-I mismatch with their donors or with a strong post-transplant reduction in CD8 + T cell number. 8 More recently, we reported that a polymorphism in programmed cell death-1 (PDCD-1) gene affected the specific CMV immune response and the survival of CMV-infected grafts. 12 Altogether, these data suggest that anti-CMV CD8 T cells have an important role in controlling CMV replication within the kidney graft and preventing chronic damage.
The effect of donor CMV infection on the CMV-specific T cell response is not yet well known. In addition, the role of CMV-infected donor cells in the development of the CMV immune response remains poorly understood. In this retrospective cross-sectional study of kidney transplant patients, we report that donor CMV infection deeply affects the CMV-specific immune response. This effect requires HLA-I matching between the donor and recipient. Finally, we provide some evidence that donor-shared HLA-I is crucial for the development of CMV-specific CD8 + T cells.
| MATERIAL S AND ME THODS

| Patients
In this study, we enrolled 115 kidney transplant adult recipients exposed to CMV (D+ and/or R+) who were followed up at Tours University Hospital. Samples were obtained when CMV disease was not suspected, at least one year after transplantation.
Initial immunosuppression involved methylprednisolone, polyclonal antilymphocyte globulins (Thymoglobuline) or basiliximab. The maintenance immunosuppressive regimen was mycophenolate mofetil or enteric-coated mycophenolate sodium, cyclosporine, tacrolimus, mammalian target of rapamycin inhibitors (sirolimus or everolimus) and prednisone as previously described. 
| Cell preparation
Peripheral blood mononuclear cells (PBMCs) were obtained after informed signed consent. Cells were isolated from whole blood by
Ficoll hypaque density-gradient (Lymphoprep; AbCys). After two washes in RPMI-1640 medium, PBMCs were suspended and incubated for functional assays.
| Measurement of cytokine production after CMV pp65 stimulation (ELISPOT)
Plates were coated with interferon-ɣ (IFN-ɣ; Mabtech 3420-2APW-Human-IFN-ɣ ELISpot PRO kit), tumor necrosis 
| Measurement of anti-CMV pp65 CD8 + T cells
The number of CMV-specific CD8 + T cells was determined in HLA- 
| Statistical analysis
Data are expressed as number (%) or mean ± SD for normally 
| RE SULTS
| Patients' characteristics
The characteristics of donors and recipients at the time of transplantation and at three-month follow-up are in Table 1 for all recipients (n = 115) and for D+R− (n = 31), D+R+ (n = 44), and D−R+ recipients (n = 40). Otherwise, prophylaxis was more often given to D+R+ than D−R+ recipients (57% vs. 33%, P = .025). No other significant difference was observed ( Table 1 ). The frequency of CMV viremia (n = 55) and CMV disease (n = 10) was greater for D+R− than other recipients but similar for D+R+ and D−R+ recipients. CMV prophylaxis was based on valganciclovir for all patients except 3 D+R− patients who received valaciclovir.
| Donor CMV infection drives the expansion of CMV pp65-responsive blood-borne T cells
We analyzed the T cell response to CMV pp65 stimulation accord- Altogether, these results argue for a pivotal role of the presentation of CMV peptides by donor cells to stimulate the expansion of CMV pp65-specific memory CD8 + T cells.
All (n = 115) D+R− (n = 31) D+R+ (n = 44) D−R+ (n = 40) D+R− vs. D+R+ D+R+ vs. D−R− D+R− vs. D−R+
| Donor-type HLA shaped CMV-specific immune response in CMV-naïve recipients
To ensure that the CMV-specific T cells we analyzed had developed after transplantation, we studied recipients who were primary- We next assessed the impact of donor HLA on the development of anti-CMV T cells according to history of CMV viremia ( Figure 3B ).
Indeed, we hypothesized that CMV antigens may have disseminated and gained access to recipient APCs within SLOs during a viremia episode, and we wondered whether recipients with a history of viremia may be more likely to develop any clones restricted by recipient-type HLA-I. Otherwise, CMV antigens may stay localized within the kidney in nonviremic patients and thus the CMV response would become highly dependent on the presentation by donor-type HLA. First, we observed that the effect of donor HLA-I on the development of CMV-specific CD8 + T cells remained strong in recipients with a CMV viremia history (P = .013; Table 2 ). Importantly, CMV TA B L E 2 Number of CMV pp65-specific CD8+ T cells in D+R− recipients 
| D ISCUSS I ON
The impact of donor CMV infection on the post-transplantation specific immune response to CMV, especially anti-CMV CD8 + T cells, and even the involvement of CMV replication, has rarely been studied. Experimental models have suggested that a large proportion of mouse CMV (MCMV) viremia in D+R+ recipients originated from the recipient. 18, 19 However, later, a dominant MCMV resistance trait expressed by C57BL/6 mice used as recipients in these studies was suggested, which therefore limited the scope of these results. 20 In contrast, among human kidney transplant recipients, seropositive recipients could be reinfected by a new CMV strain from the donor after transplantation. 21 Our results indicate that donor CMV infection drives a specific CMV immune response and suggest that the donor CMV reactivates after transplantation and then stimulates anti-CMV lymphocytes in the recipient. Moreover, because the amplitude of the T cell response is correlated with the size of the viral inoculum, the effect of donor CMV infection on the CMV-specific response indicates that CMV reactivation in donor cells is frequent and significant.
22
The relative weight of the donor and recipient CMV presentation on amplification of the CMV immune response after transplantation is unknown. The CMV-specific CD8 + T cell response is greater than the CD4 + T cell response. 15 Shabir et al reported that specific donor HLA-I had no role in generating CMV-specific CD8 + T cells after kidney transplantation. How the blood-borne CMV-specific CD8 + T cells participate to control the CMV replication inside the graft remains disputed. This is an important point because we and others have reported that donor CMV infection has been associated with a poor graft outcome, 8, 25, 26 and a few studies have shown that CMV replication within the kidney graft promotes chronic allograft dysfunction.
9,11
Lin et al recently classified organs according to their accessibility to CD8 + T cells. 5 The authors considered the kidney as a permissive organ, meaning that it can recruit CD8 + T cells even in the absence of inflammatory conditions in order to quickly and efficiently control CMV reactivation along tissue-resident memory T cells. We reported a higher number of IFN-ɣ-producing CMVspecific T cells and better kidney graft survival in kidney transplant recipients carrying a genetic variant in PDCD1 than wild-type homozygous patients. 12 This report, replicated in lung transplant recipients, might indirectly suggest that the CMV-specific T cell response reflects the ability to control graft damage associated with donor CMV infection.
In conclusion, we give for the first time valuable evidence that CMV-infected donor cells directly drive inflation of memory CMVspecific CD8 + T cells in kidney transplant recipients.
